• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MedImmune

MedImmune

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Amgen to terminate participation in co-development and commercialization of brodalumab

    Amgen to terminate participation in co-development and commercialization of brodalumab

  2. Research and Markets: Global Anal Cancer Pipeline Report 2015 - 6 Companies & 6 Drug Profiles

    Research and Markets: Global Anal Cancer Pipeline Report 2015 - 6 Companies & 6 Drug Profiles

  3. Immune Pharmaceuticals Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready to Enroll Patients

    Immune Pharmaceuticals Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready to Enroll Patients

  4. Immune Pharmaceuticals and STC Biologics announce strategic partnership to accelerate the development of NanomAbs®

    Immune Pharmaceuticals and STC Biologics announce strategic partnership to accelerate the development of NanomAbs®

  5. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  6. Biotech Investing for the Long Haul

    Three ways to separate long-term winners from stocks that fizzle.

  7. Morningstar Indexes: Weekly Market Report

    Week ending April 27: Quarterly earnings continue to boost market's spirits. 

  8. Services Super Sector: Major Themes

    Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.